Actively Recruiting
A Prospective Cohort Study on Drug-induced Liver Injury in China（DILI-P）
Led by Drug Induced Liver Disease Study Group · Updated on 2025-05-04
10000
Participants Needed
1
Research Sites
765 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multi-center, prospective, non-interventional cohort study . Its primary objectives are: 1. assess DILI patients' clinical characteristics, disease progression and influencing factors in clinical practice; 2. learn about suspected drug caused DILI,rechallenging, liver biochemical abnormalities mode, etc.
CONDITIONS
Official Title
A Prospective Cohort Study on Drug-induced Liver Injury in China（DILI-P）
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of drug-induced liver injury according to the 2015 Chinese DILI treatment guidelines
- RUCAM score of 6 or higher, or RUCAM between 3 and 5 confirmed by three experts as drug-induced liver injury
- Ability to provide informed consent
You will not qualify if you...
- Liver injury not caused by drugs
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Renji hospital
Shanghai, China
Actively Recruiting
Research Team
C
Chunxia Zhang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here